Global Respiratory Drugs Pipeline Analysis Market 2018

Overview: Pulmonary medicine is the branch of medical science that deals with diagnosis, prevention, and treatment of diseases affecting the respiratory system. Respiratory drugs finds its applications in Asthma, COPD, Cystic Fibrosis, Allergic Rhinitis and Others. Asthma is the major market share holder currently. The intensity of competition in the respiratory drug market is high with few players dominating the market. The high investments made in the development of respiratory drug delivery systems have favored the growth of the market. The entry of innovative and effective drugs in the market is expected to drive the future of the market.

Short-Acting Beta2-Agonists (SABA), Inhaled corticosteroids (ICS), anticholinergics, long-acting beta2-agonists (LABA), antihistamines, vasodilators, combination drugs, and others are the major respiratory dugs classes available in the market. Currently, primarily combination drugs drive the market, with top brands facing no real competition from generic alternatives. The emergence of inexpensive, state-of-the-art and effective drug delivery devices will provide stimulate the market growth.

Industry Trends

  • GSK’s Adavir for Asthma and COPD remains as the top selling drug in the market, even on declined revenue in 2017
  • Pharmaceutical companies in US are facing pricing pressure and launch of new respiratory drugs in the market are declining the sales of the blockbuster drugs in the market
  • Cipla Ltd., a leader in the Indian market, announced in May 2017, that it planned to reduce the investment on the biosimilars, to increase their focus on the respiratory drugs due to the high profitability

More than 30 companies pipeline for the respiratory drugs is analyzed in the study.  GlaxoSmithKline plc has the highest number of pipeline molecules in various clinical trials phases.

Benefits: The report provides complete details about the usage and adoption rate of respiratory drugs in various regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player’s initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

Key Stakeholders:

respiratory drugs pipeline analysis

1     Industry Outlook 

1.1        Industry Overview

1.1.1     Global Driver for Pharmaceutical Demand:

1.1.2     Pharmaceutical spending region wise

1.1.3     R&D pipeline in pharmaceutical industry

1.1.4     Top pharma drugs by sales in 2017 ($Million)

1.2        Industry Trends

1.3        Pest Analysis

2     Report Outline 

2.1        Report Scope

2.2        Report Summary

2.3        Research Methodology

2.4        Report Assumptions

3     Market Snapshot 

3.1        Market Definition – Infoholic Research

3.2        Segment Addressable Market

3.1        Trends of Respiratory Drugs Market

4     Molecule Type: Analysis 

4.1        Overview

5     Application: Analysis 

5.1        Overview

5.2        Asthma

5.2.1     Key Takeaways

5.2.2     Company Analysis

5.3        Chronic Obstructive Pulmonary Disease (COPD)

5.3.1     Key Takeaways

5.3.2     Company Analysis

5.4        Cystic Fibrosis

5.4.1     Key Takeaways

5.4.2     Company Analysis

5.5        Lung Cancer

5.5.1     Key Takeaways

5.5.2     Company Analysis

5.6        Nasal Polyps

5.6.1     Key Takeaways

5.7        Idiopathic Pulmonary Fibrosis

5.7.1     Key Takeaways

5.7.2     Company Analysis

5.8        Others

6     Competitive Landscape 

6.1.1     Company Analysis

7     Vendors Profile 

7.1        AbbVie Inc.

7.1.1     Overview

7.1.2     Geographic Presence

7.1.3     Business Focus

7.1.4     SWOT Analysis

7.1.5     Business Strategies

7.2        Amgen Inc.

7.2.1     Overview

7.2.2     Geographic Presence

7.2.3     Business Focus

7.2.4     SWOT Analysis

7.2.5    Business Strategies

7.3        Astra Zeneca PLC

7.3.1     Overview

7.3.2     Geographic Presence

7.3.3     Business Focus

7.3.4     SWOT Analysis

7.3.5     Business Strategy

7.4        Bayer AG

7.4.1     Overview

7.4.2     Business Unit

7.4.3     Geographic Presence

7.4.4     Business Focus

7.4.5     SWOT Analysis

7.4.6     Business Strategy

7.5        Boehringer Ingelheim GmbH

7.5.1     Overview

7.5.2     Geographic Presence

7.5.3     Business Focus

7.5.4     SWOT Analysis

7.5.5     Business Strategy

7.6        Bristol-Myers Squibb

7.6.1     Overview

7.6.2     Geographic Presence

7.6.3     Business Focus

7.6.4     SWOT Analysis

7.6.5     Business Strategy

7.7        Celgene Corporation

7.7.1     Overview

7.7.2     Geographic Presence

7.7.3     Business Focus

7.7.4     SWOT Analysis

7.7.5     Business Strategy

7.8        Dr. Reddy’s Laboratories Limited

7.8.1     Overview

7.8.2     Business Unit

7.8.3     Geographic Presence

7.8.4     Business Focus

7.8.5     SWOT Analysis

7.8.6     Business Strategy

7.9        Eli Lilly & Company Ltd

7.9.1     Overview

7.9.2     Business Focus

7.9.3     SWOT Analysis

7.9.4     Business Strategies

7.10     F.Hoffmann-La Roche Ltd.

7.10.1  Overview

7.10.2  Business Unit

7.10.3  Geographic Presence

7.10.4  Business Focus

7.10.5  SWOT Analysis

7.10.6  Business Strategy

7.11     GlaxoSmithKline plc

7.11.1  Overview

7.11.2  Geographic Presence

7.11.3  Business Focus

7.11.4  SWOT Analysis

7.11.5  Business Strategy

7.12     Johnson & Johnson

7.12.1  Overview

7.12.2  Business Units

7.12.3  Geographic Revenue

7.12.4  Business Focus

7.12.5  SWOT Analysis

7.12.6  Business Strategies

7.13     Merck & Co., Inc.

7.13.1  Overview

7.13.2  Business units

7.13.3  Geographic Revenue

7.13.4  Business focus

7.13.5  SWOT analysis

7.13.6  Business strategies

7.14     Mylan N.V.

7.14.1  Overview

7.14.2  Geographic Presence

7.14.3  Business Focus

7.14.4  SWOT Analysis

7.14.5  Business Strategy

7.15     Novartis AG

7.15.1  Overview

7.15.2  Business Unit

7.15.3  Geographic Presence

7.15.4  Business Focus

7.15.5  SWOT Analysis

7.15.6  Business Strategy

7.16     Pfizer, Inc.,

7.16.1  Overview

7.16.2  Business Units

7.16.3  Geographic Presence

7.16.4  Business Focus

7.16.5  SWOT Analysis

7.16.6  Business Strategies

7.17     Sanofi

7.17.1  Overview

7.17.2  Geographic Presence

7.17.3  Business Focus

7.17.4  SWOT Analysis

7.17.5  Business Strategy

7.18     Teva Pharmaceutical Industries Ltd.

7.18.1  Overview

7.18.2  Business Unit

7.18.3  Geographic Presence

7.18.4  Business focus

7.18.5  SWOT analysis

7.18.6  Business Strategy

7.19     Vertex Pharmaceuticals Inc.

7.19.1  Overview

7.19.2  Geographic Presence

7.19.3  Business Focus

7.19.4  SWOT Analysis

7.19.5  Business Strategy

8     Companies to Watch For 

8.1        FibroGen, Inc

8.1.1     Overview

8.1.2     Highlights

8.2        Gilead Sciences Inc.

8.2.1     Overview

8.2.2     Highlights:

8.3        Glenmark Pharmaceutical Ltd

8.3.1     Overview

8.4        Zia Labs

8.4.1     Overview

8.4.2     Zia Lab: Highlights

8.5        Vectura Group Plc

8.5.1     Overview

8.5.2     Vectura Group Plc: Highlights

8.6        Sosei Group Corporation

8.6.1     Overview

8.7        Almirall S.A.

8.7.1     Overview

8.8        Biogen Inc

8.8.1     Overview

8.9        CHIESI Farmaceutici SpA

8.9.1     Overview

8.9.2     CHIESI Farmaceutici SpA: Highlights

8.10     Takeda Pharmaceutical Co, Ltd

8.10.1  Overview

8.10.2  Highlights

8.11     Shionogi & Co., Ltd

8.11.1  Overview

8.11.2  Shionogi & Co., Ltd: Highlights

8.12     Sun Pharmaceuticals

8.12.1  Overview

8.12.2  Highlights

8.13     United Therapeutics Corp

8.13.1  Overview

8.13.2  Highlights

8.14     ProMetic Life Sciences Inc.

8.14.1  Overview

8.14.2  ProMetic Life Sciences Inc.: Highlights

8.15     Daiichi Sankyo, Inc.

8.15.1  Overview

8.15.2  Overview

8.16     Aurobindo Pharma Ltd

8.16.1  Overview

8.16.2  Aurobindo Pharma Ltd: Highlights

8.17     Eisai Co., Ltd

8.17.1  Overview

8.17.2  Eisai Co., Ltd: Highlights

8.18     Shire Plc

8.18.1  Overview

8.18.2  Shire Plc: Highlights

8.19     GNI Group Ltd

8.19.1  Overview

8.20     MediciNova, Inc

8.20.1  Overview

8.21     Ono Pharmaceutical Co., Ltd

8.21.1  Overview

8.22     Promedior, Inc

8.22.1  Overview

8.23     Sumitomo Dainippon Pharma Co., Ltd.

8.23.1  Overview

8.23.2  Sumitomo Dainippon Pharma Co., Ltd: Highlights

9     Annexure
Abbreviations

Infoholic research works on a holistic 360° approach in order to deliver high quality, validated and reliable information in our market reports. The Market estimation and forecasting involves following steps:

  • Data Collation (Secondary & Primary)
  • In-house Estimation (Based on proprietary data bases and Models)
  • Market Triangulation
  • Forecasting

methodology

Market related information is congregated from both secondary and primary sources. Secondary sources include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications along with paid sources such as Factiva, OneSource, Bloomberg among others.

Primary sources involved participants from all global stakeholders such as Solution providers, service providers, Industry associations, thought leaders etc. across levels such as CXOs, VPs and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.

For more details on Research Methodology kindly click here to Engage with our Analyst.

  • 188
    Pages

  • 88
    Tables

  • 80
    Charts

  • 42
    Companies

  • 10
    Enquiry Hours